Table 1.
Gout patients who were prescribed ULT and proportion of allopurinol, benzbromarone, and febuxostat prescription
| Year | Total gout | ULT | Allopurinol | Benzbromarone | Febuxostat |
|---|---|---|---|---|---|
| 2007 | 169,796 | 146,261 (86.1) | 140,887 (96.3) | 5,374 (3.7) | 0 |
| 2008 | 189,231 | 161,674 (85.4) | 155,303 (96.1) | 6,371 (3.9) | 0 |
| 2009 | 208,247 | 178,360 (85.6) | 170,662 (95.7) | 7,698 (4.3) | 0 |
| 2010 | 233,397 | 198,750 (85.2) | 189,862 (95.5) | 8,888 (4.5) | 0 |
| 2011 | 253,975 | 213,299 (84.0) | 203,930 (95.6) | 9,369 (4.4) | 0 |
| 2012 | 285,838 | 237,238 (83.0) | 213,260 (89.9) | 10,062 (4.2) | 13,916 (5.9) |
| 2013 | 321,419 | 265,219 (82.5) | 221,623 (83.6) | 10,335 (3.9) | 33,261 (12.5) |
| 2014 | 346,685 | 285,466 (82.3) | 236,106 (82.7) | 10,809 (3.8) | 38,551 (13.5) |
| 2015 | 383,471 | 313,098 (81.6) | 257,912 (82.4) | 10,827 (3.5) | 44,359 (14.2) |
Values are presented as number (%).
ULT, urate-lowering therapy.